Table 3. Clinical and Non-Clinical Changes of Some Parameters in Three Groups of Intervention.
| FBS a, mmol/L | TG a, mg/dL | CHOL a, mg/dL | ALT a, IU/L | AST a, IU/L | HOMA-IR a | |||||||
| Pre No. (%) | Post No. (%) | Pre No. (%) | Post No. (%) | Pre No. (%) | Post No. (%) | Pre No. (%) | Post No. (%) | Pre No. (%) | Post No. (%) | Pre No. (%) | Post No. (%) | |
| Pioglitazone | ||||||||||||
| Clinical | 7 (31.82) | 0 (0) | 22 (100) | 22 (100) | 11 (50) | 7 (31/82) | 22 (100) | 16 (72.73) | 22 (100) | 7 (31.82) | 12 (54.55) | 5 (22.73) |
| Non-clinical | 15 (68.18) | 22 (100) | 0 (0) | 0 (0) | 11 (50) | 15 (68.18) | 0 (0) | 6 (27.27) | 0 (0) | 15 (68.18) | 10 (45.45) | 17 (77.27) |
| Metformin | ||||||||||||
| Clinical | 5 (22.73) | 0 (0) | 22 (100) | 22 (100) | 9 (40.91) | 6 (27.27) | 22 (100) | 20 (90.91) | 20 (90.91) | 10 (45.45) | ||
| 13 (59.1) | 8 (36/36) | |||||||||||
| Non-clinical | 17 (77.27) | 22 (100) | 0 (0) | 0 (0) | 13 (59.09) | 16 (72.73) | 0 (0) | 2 (9.09) | 2 (9.09) | 12 (54.55) | 9 (4.9) | 14 (63.64) |
| Silymarin | ||||||||||||
| Clinical | 6 (27.27) | 3 (13.64) | 22 (100) | 22 (100) | 10 (45.45) | 7 (31.8) | 22 (100) | 18 (81.8) | 22 (100) | 8 (36.4) | 13 (59.1) | 13 (59.1) |
| Non-clinical | 16 (72.73) | 19 (86.36) | 0 (0) | 0 (0) | 12 (54.55) | 5 (68.2) | 0 (0) | 4 (18.2) | 0 (0) | 14 (63.6) | 9 (40.9) | 9 (40.9) |
| Total | ||||||||||||
| Clinical | 18 (72. 7) | 3 (4.5) | 66 (100) | 66 (100) | 30 (45.46) | 20 (30.3) | 66 (100) | 54 (81.8) | 64 (97) | 25 (37.88) | 8 (42.4) | 20 (30.3) |
| Non-clinical | 48 (27.3) | 63 (95.5) | 0 (0) | 0 (0) | 30 (54.55) | 46 (69.7) | 0 (0) | 12 (18.2) | 2 (3) | 41 (62.12) | 28 (54.6) | 40 (60.6) |
aAbbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHOL, cholesterol; FBS, fasting blood sugar; HOMA-IR, homeostasis model assessment index for insulin resistance; TG, triglyceride